Ioversol

Identification

Name
Ioversol
Accession Number
DB09134
Description

Ioversol is classified as an organoiodine compound and is used as a contrast dye in diagnostic procedures. It contains high levels of iodine in addition to various hydrophilic groups.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 807.115
Monoisotopic: 806.86466
Chemical Formula
C18H24I3N3O9
Synonyms
  • Ioversol
  • N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
  • Optiray
External IDs
  • MP 328
  • MP-328
  • MP328

Pharmacology

Indication

Optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. Optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. Optiray 350 is indicated in children for angiocardiography. Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Optiray enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.

Absorption

Ioversol may be visualized in the renal parenchyma within 30 to 60 seconds following rapid intravenous injection. Opacification of the calyces and pelves in patients with normal renal function becomes apparent within 1 to 3 minutes, with optimum contrast occurring within 5 to 15 minutes.

Volume of distribution
Not Available
Protein binding

Ioversol does not bind to serum or plasma proteins.

Metabolism

No significant metabolism, deiodination or biotransformation occurs.

Route of elimination

Ioversol is excreted mainly through the kidneys following intravascular administration. Greater than 95% of the administered dose was excreted within the first 24 hours, with the peak urine concentration occurring in the first 2 hours after administration. Fecal elimination was negligible.

Half-life

1.5 hr

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events. Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Ioversol which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ioversol which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcrivastineIoversol may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Ioversol which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Optiray 160Solution34 %IntravenousTyco Healthcare1992-12-312010-08-05Canada flag
Optiray 160Injection339 mg/1mLIntravascularMallinckrodt Inc.2007-03-232007-03-23US flag
Optiray 160 (ultraject)SolutionIntravascularTyco HealthcareNot applicableNot applicableCanada flag
Optiray 240Solution51 %Intravascular; SubarachnoidLiebel Flarsheim Company Llc1996-11-20Not applicableCanada flag
Optiray 240Injection509 mg/1mLIntra-arterial; IntravenousLiebel-Flarsheim Company LLC2012-03-04Not applicableUS flag
Optiray 240 (ultraject)SolutionIntravascular; SubarachnoidLiebel Flarsheim Company Llc1996-12-31Not applicableCanada flag
Optiray 240 Inj 240mg/mlLiquidIntravascularMallinckrodt1992-12-312014-12-10Canada flag
Optiray 300Solution64 %IntravascularLiebel Flarsheim Company Llc1998-03-03Not applicableCanada flag
Optiray 300Injection636 mg/1mLIntra-arterial; IntravenousLiebel-Flarsheim Company LLC2012-03-04Not applicableUS flag
Optiray 300 (ultraject)SolutionIntravascularLiebel Flarsheim Company LlcNot applicableNot applicableCanada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
V08AB07 — Ioversol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylaminobenzoic acid and derivatives
Alternative Parents
2-halobenzoic acids and derivatives / 4-halobenzoic acids and derivatives / Anilides / Benzamides / Benzoyl derivatives / Iodobenzenes / Aryl iodides / Vinylogous halides / Tertiary carboxylic acid amides / Secondary alcohols
show 8 more
Substituents
2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Acylaminobenzoic acid or derivatives / Alcohol / Alkanolamine / Anilide / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Benzamide
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
N3RIB7X24K
CAS number
87771-40-2
InChI Key
AMDBBAQNWSUWGN-UHFFFAOYSA-N
InChI
InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
IUPAC Name
N1,N3-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
SMILES
OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

References

General References
  1. Morimoto S, Kozuka T, Takamiya M, Kimura K, Matsuyama S, Kuribayashi S, Shigeta A, Umemura J, Harada J, Yamada T, et al.: [Usefulness of ioversol (MP-328) in angiocardiography--a multicenter comparative study with iopamidol]. Nihon Igaku Hoshasen Gakkai Zasshi. 1990 Sep 25;50(9):1087-101. [PubMed:2247350]
KEGG Drug
D01555
PubChem Compound
3741
PubChem Substance
310265049
ChemSpider
3610
RxNav
27792
ChEBI
31717
ChEMBL
CHEMBL1200614
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ioversol
AHFS Codes
  • 36:68.00 — Roentgenography
FDA label
Download (6.99 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingOtherHypothyroidism1
4TerminatedOtherImpaired kidney function1
4WithdrawnDiagnosticCoronary Artery Disease (CAD) / Diabetes Mellitus / Impaired kidney function1
0CompletedScreeningAcute Myeloid Leukemia (AML) / Leukemia, Myelogenous, Chronic / Multiple Myeloma (MM) / Myelodysplastic Syndromes (MDS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution160 MG/ML
Injection, solution240 MG/ML
Injection, solution300 MG/ML
Injection, solution320 MG/ML
Injection, solution350 MG/ML
SolutionIntravenous741 mg
InjectionIntravascular339 mg/1mL
SolutionIntravenous34 %
InjectionIntra-arterial; Intravenous509 mg/1mL
SolutionIntravascular; Subarachnoid51 %
SolutionIntravascular; Subarachnoid
LiquidIntravascular
Injection, solutionIntra-arterial; Intravenous509 mg/ml
SolutionIntra-arterial; Intravenous509 mg/ml
InjectionIntra-arterial; Intravenous636 mg/1mL
SolutionIntravascular64 %
SolutionIntra-arterial; Intravenous636 mg/ml
InjectionIntra-arterial; Intravenous678 mg/1mL
SolutionIntravascular68 %
SolutionIntra-arterial; Intravenous678 mg/ml
InjectionIntra-arterial; Intravenous741 mg/1mL
SolutionIntravascular74 %
SolutionIntravascular
SolutionIntra-arterial; Intravenous741 mg/ml
SolutionIntravenous678 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.04 mg/mLALOGPS
logP-3ALOGPS
logP-2.1ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)11.72ChemAxon
pKa (Strongest Basic)-2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area199.89 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity144.58 m3·mol-1ChemAxon
Polarizability58.31 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on September 29, 2015 16:11 / Updated on September 27, 2020 08:17

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates